AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Exclusion criteria

• . Has a diagnosis of immunodeficiency.
• . Prior stem cell, bone marrow, or organ transplant.
• . Known history of HIV infection. No HIV testing is required unless mandated by local health authority.
• . History of HBV (defined as HBV surface antigen reactive) or active HCV.
• . Active autoimmune disease (non-immunotherapy induced conditions) that has required systemic treatment in the past two years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic immune-suppressive treatment and is allowed.
• . Active Grade ≥2 diarrhea or enterocolitis.
• . Known active CNS metastases and/or carcinomatous meningitis. Individuals with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression for at least two weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment).
• . Any other current or previous malignancy within the previous three years except neoplasms that, in the opinion of the treating investigator and with the agreement of the sponsor-investigator, will not interfere with study-specific endpoints, e.g. basal cell carcinoma, localized tumors that have been fully excised with curative intent and no evidence of recurrence or metastasis, prostate cancer that is asymptomatic and does not require therapy other than anti-androgen therapy.